Jan 09, 2024 / NTS GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the AstraZeneca presentation. So you're going to hear from AstraZeneca CFO, Aradhana Sarin. Thank you very much for joining us today, Aradhana. Really looking forward to the presentation.
Aradhana Sarin - AstraZeneca PLC - CFO & Executive Director
Thank you, James, and JPMorgan for hosting us this year. Good afternoon, everyone. It's a pleasure to be here with all of you to share the remarkable progress that AstraZeneca has made over the course of 2023 and explain some of the factors that underpin our confidence in delivering industry-leading growth through 2030 and beyond.
On this slide, you'll see some of our forward-looking statements, which I urge you to take a moment to review when you have a chance. This is an exciting time to be at AstraZeneca. In the first 9 months of 2023, we delivered $34 billion in revenue with ex-COVID medicines up 15%
AstraZeneca PLC at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers